Clinical Trials Logo

Moderate to Severe Acne Vulgaris clinical trials

View clinical trials related to Moderate to Severe Acne Vulgaris.

Filter by:
  • None
  • Page 1

NCT ID: NCT06378983 Recruiting - Clinical trials for Moderate to Severe Acne Vulgaris

Clinical Trial of Microneedle Radiofrequency Combined With Oral Isotretinoin in Moderate to Severe Acne

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study plans to select 100 AV patients and randomly divide them into two groups in a 1:1 ratio: the experimental group will be treated with MRF combined with oral isotretinoic acid for 8 consecutive weeks, with a total of 3 MRF treatments at weeks 1, 4, and 8. The control group received oral administration of isotretinoic acid alone for 8 weeks. The main observation indicators are the percentage of effective skin injury clearance achieved by subjects at week 20, as well as the change in ECCA acne scar score compared to baseline at week 20. I hope this study can clarify that the combination therapy of the two can achieve the effects of improving efficacy, shortening treatment course, reducing recurrence, not increasing adverse reactions, and reducing the risk of scar formation.

NCT ID: NCT06315166 Recruiting - Clinical trials for Moderate to Severe Acne Vulgaris

Study on Using Radiofrequency to Treat Moderate to Severe Acne

Start date: April 10, 2024
Phase: N/A
Study type: Interventional

Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.

NCT ID: NCT04163263 Completed - Clinical trials for Moderate to Severe Acne Vulgaris

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Start date: November 4, 2019
Phase: Phase 1
Study type: Interventional

This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application